Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

KalVista designs enlarged phase II study for KVD-900 in HAE

Nov. 13, 2018

Small-molecule hepcidin production inhibitor developed for treatment of anemia of chronic disease

Nov. 12, 2018

Codexis announces topline results from phase Ia study of CDX-6114

Nov. 9, 2018

Study points to new bone building strategy

Nov. 9, 2018

DSMB recommends discontinuation of phase III study of PREOB for osteonecrosis

Nov. 7, 2018

Corcept Therapeutics enrolling participants in phase III study of relacorilant

Nov. 7, 2018

Fat and fibroblasts

Nov. 7, 2018

REWIND study of Trulicity meets primary efficacy objective

Nov. 6, 2018

A 20p11.2 deletion including FOXA2 causes hyperinsulinemic hypoglycemia

Nov. 5, 2018

First mouse model of Costello syndrome highlights role of altered metabolism in disease

Nov. 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...